Population-based study of risk of venous thromboembolism associated with various oral contraceptives

Lancet

Volumn 349, Issue 9045, 1997, Pages 83-88

  Farmer, R D T ^a   Lawrenson, R A ^a   Thompson, C R ^a   Kennedy, J G ^a   Hambleton, I R ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0031035173     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07496-X     Document Type: Article

References (6)

1. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-88.
2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk or idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
3. Spitzer WO, Lewis MA, Heinemann AJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-88.
4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995; 346: 1593-96.
5. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52.
6. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 302.